meRfi®-GM
The Digital Textbook on Gut Microbiota and Beyond
Alzheimer’s Disease (AD) & Lipopolysaccharides (LPS)
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Lipopolysaccharides (LPS) has a strong affinity for chylomicron lipoproteins
Some researchers have proposed that certain elements of the gut microbiota, including Bacillus subtilis and Escherichia coli (E. coli), produce significant quantities of lipopolysaccharides and amyloid proteins.
As i…
References (Sources)
- Alzheimer’s disease and gut microbiota modifications: The long way between preclinical studies and clinical evidence
- Connection between gut microbiome and the development of obesity
- Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice
- Microglial activation is required for Abeta clearance after intracranial injection of lipopolysaccharide in APP transgenic mice
- Of microbes and minds: a narrative review on the second brain aging
- Secretory Products of the Human GI Tract Microbiome and Their Potential Impact on Alzheimer's Disease (AD): Detection of Lipopolysaccharide (LPS) in AD Hippocampus
- The gut microbiota and Alzheimer’s disease